---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-25-000071"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T23:07:26.674223+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio Q3 net loss $14.6M; all-stock merger with Clywedog

## Summary
- Net loss of $14.6M ($0.36/share) in Q3 2025 vs $21.1M loss in Q2 2025.
- Cash and equivalents $75.7M as of Sept 30, down $12.1M from June 30; runway into 2027.
- Announced all-stock merger with Clywedog; combined company renamed Clywedog Therapeutics Holdings, ticker CLYD, close expected H1 2026.
- VTP-1000 celiac SAD data expected by end 2025; MAD data in H2 2026.
- Impairment of $4.7M due to deal valuation; R&D expenses fell to $5.4M from $8.0M QoQ.

## SEC filing metadata
- accession: 0001828185-25-000071
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000071/0001828185-25-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000071/brns-20251107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-25-000071
- JSON: https://secwatch.observer/filing/0001828185-25-000071.json
- Plain text: https://secwatch.observer/filing/0001828185-25-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.